01808nas a2200337   4500000000100000008004100001260001300042653002400055653002600079653002400105653003800129653001600167653001100183653001600194653001200210653002500222653003000247653002900277100001200306700001500318700001200333700001600345700001500361700001400376245008900390856007800479300001000557490000700567520088200574022001401456       1990                            d  c1990 Mar10aAgglutination Tests10aAntibodies, Bacterial10aAntigens, Bacterial10aEnzyme-Linked Immunosorbent Assay10aGlycolipids10aHumans10aImmune Sera10aleprosy10aMycobacterium leprae10aPredictive Value of Tests10aReagent Kits, Diagnostic1 aIzumi S1 aFujiwara T1 aIkeda M1 aNishimura Y1 aSugiyama K1 aKawatsu K00aNovel gelatin particle agglutination test for serodiagnosis of leprosy in the field.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC269656/pdf/jcm00051-0133.pdf  a525-90 v283 a<p>We developed a novel gelatin particle agglutination test (MLPA) for the serodiagnosis of leprosy; this test is especially useful for clinical practice and epidemiological surveys of leprosy in countries in which the disease is endemic. The antigen used in the test is the chemically synthesized trisaccharide moiety of Mycobacterium leprae-specific phenolic glycolipid I. MLPA is a simple and easy technique having sensitivity and specificity comparable to those of the conventional indirect enzyme-linked immunosorbent assay. The new technique was found to be useful for monitoring of chemotherapy and predictive diagnosis of high-risk individuals in contact with persons with leprosy and may be useful for the prediction of relapse. We are now preparing to supply a quality-controlled ready-to-use MLPA kit for leprosy control in countries in which leprosy is endemic.</p>  a0095-1137